Table 2.

Association between ABCB1 2677G>T/A genotypes and progression-free and overall survival

ABCB1 genotypeCases, n (%)*Relapse, n (%)Died, n (%)Progression-free survival, HR (95% CI), P value
UnadjustedAdjusted
2677G>T/A
    GG91 (30.3)66 (36.7)28 (36.4)1.001.00
    GA/GT141 (47.0)77 (42.8)32 (41.5)0.62 (0.44-0.86), P = 0.0040.74 (0.52-1.05), P = 0.1
    TT/TA68 (22.7)37 (20.6)17 (22.1)0.60 (0.40-0.89), P = 0.0130.74 (0.48-1.14), P = 0.2
    GA/GT + TT/TA209 (69.7)114 (63.3)49 (63.6)0.61 (0.45-0.83), P = 0.0020.74 (0.54-1.03), P = 0.07
3435C>T
    CC80 (26.0)44 (23.7)20 (26.0)1.001.00
    CT148 (48.0)91 (48.9)32 (41.5)1.13 (0.79-1.62), P = 0.51.00 (0.68-1.46), P = 1.0
    TT80 (26.0)51 (27.4)25 (32.5)1.22 (0.81-1.82), P = 0.31.06 (0.69-1.63), P = 0.8
1236C>T
    CC94 (30.6)55 (29.6)26 (33.8)1.001.00
    CT156 (50.8)92 (49.4)36 (46.7)1.00 (0.71-1.39), P = 1.01.18 (0.83-1.68), P = 0.4
    TT57 (18.6)39 (21.0)15 (19.5)1.14 (0.75-1.72), P = 0.51.03 (0.66-1.61), P = 0.9
  • * n does not sum to 309 due to missing genotype data.

  • χ2 test for trend in progression-free or overall survival by increasing number of T/A alleles.

  • Adjusted for FIGO stage and residual disease.